Key Takeaways
- Novartis AG's U.S.-listed shares ($NVS) plummeted 8.7% to $94.20 on Tuesday, marking its largest single-day decline since February 2021.
- The pharmaceutical giant's market capitalization shed approximately $20 billion following news of a U.S. regulatory setback for its acquired drug, del-desiran.
- Analysts at JPMorgan Chase & Co. immediately downgraded $NVS to 'Neutral' from 'Overweight,' slashing their 12-month price target by 15% to $105.
- The issue with del-desiran, anticipated to generate over $3.5 billion in peak annual sales, casts doubt on Novartis's near-term growth trajectory and M&A strategy.
- This development puts increased pressure on Novartis's remaining pipeline assets to deliver, particularly after the company's recent strategic portfolio adjustments.
Novartis Shares Plunge on Del-Desiran Regulatory Blow
Novartis AG's U.S.-listed shares ($NVS) collapsed 8.7% to close at $94.20 on Tuesday, following an announcement that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for del-desiran, its investigational therapy for a rare neurological disorder. The CRL, indicating the agency cannot approve the drug in its current form, represents a significant setback for a key asset acquired through the $12 billion purchase of TheraGen Biosciences in late 2022. The unexpected regulatory rejection immediately triggered a wave of selling, erasing a substantial portion of the stock's gains over the past six months.
The immediate market reaction saw trading volume for $NVS surge to 18.5 million shares, nearly triple its 30-day average of 6.3 million. This sharp sell-off wiped approximately $20 billion from Novartis's market capitalization, bringing it to $198 billion. Investor sentiment soured rapidly, reflecting deep concerns over the future revenue potential of del-desiran, which was widely seen as a cornerstone of Novartis's post-spin-off growth strategy and a justification for the hefty acquisition price.
Market Impact
The 8.7% plunge in $NVS shares to $94.20 marked the stock's steepest one-day drop since February 23, 2021, when it fell 9.1% after a disappointing clinical trial readout for another pipeline candidate. This current decline pushed the stock below its 200-day moving average of $96.55, a technical level often watched by investors for long-term trend indications. The stock briefly touched an intraday low of $93.85 before paring some losses into the close.
Beyond Novartis, the news sent ripples across the broader pharmaceutical sector, particularly impacting companies with significant rare disease pipelines or recent large-scale acquisitions. The iShares Biotechnology ETF ($IBB) saw a modest decline of 1.2%, while the broader S&P 500 Pharmaceuticals Index ($SPSIPH) fell 2.1% on the day. European pharmaceutical peers like Roche Holding AG ($RHHBY) and Sanofi SA ($SNY) also experienced slight downward pressure, dipping 0.8% and 0.5% respectively, as investors re-evaluated the regulatory risks inherent in high-value drug acquisitions. The setback for del-desiran could prompt a more cautious approach to M&A in the biotech space, especially for assets nearing regulatory review.
What Analysts Are Saying
The regulatory blow for del-desiran prompted immediate revisions from a number of sell-side analysts. According to JPMorgan Chase & Co. analyst Richard Smith, "The CRL for del-desiran is a material negative surprise, fundamentally altering the risk-reward profile for $NVS. We had modeled peak sales of $3.5 billion by 2030 for this asset, and its uncertain future necessitates a significant haircut to our valuation." Smith's team downgraded $NVS to 'Neutral' from 'Overweight' and cut their 12-month price target to $105 from $124.
Analysts at UBS Group AG echoed similar concerns, with lead analyst Eleanor Vance noting, "While Novartis has a deep pipeline, del-desiran was a pivotal component of their near-term revenue diversification strategy post-Sandoz spin-off. The FDA's concerns, reportedly centered on manufacturing consistency and a need for additional clinical data to confirm long-term efficacy, suggest a lengthy delay, if not an outright abandonment." UBS maintained its 'Neutral' rating but lowered its price target to $100 from $115, citing increased uncertainty.
However, a contrarian perspective emerged from Berenberg Bank, which maintained its 'Hold' rating on $NVS, albeit with a revised price target of $108 from $118. Berenberg analyst Marcus Schmidt stated, "While the del-desiran news is undoubtedly disappointing, Novartis possesses a robust portfolio of approved medicines and several other promising late-stage assets, including its radioligand therapy pipeline and potential blockbuster Leqvio. We believe the market reaction may be overdone, creating a potential entry point for long-term investors if the broader pipeline continues to execute." Schmidt emphasized that Novartis's strong balance sheet provides flexibility to pursue other growth avenues.
What to Watch
Investors will be closely monitoring several key developments that could influence Novartis's trajectory in the wake of the del-desiran setback. First, the company's detailed response to the FDA's Complete Response Letter will be crucial. Novartis has indicated it will engage with the agency to understand the specific concerns, and any clarity on a path forward – such as a requirement for an additional Phase 3 trial or manufacturing facility upgrades – will be critical. An update is expected within the next 90 days.
Second, the market will scrutinize Novartis's upcoming first-quarter earnings call, scheduled for April 23, 2024. During this call, management is expected to provide revised financial guidance for the full year 2024, explicitly addressing the impact of del-desiran's delay or failure on projected revenues and earnings per share. Analysts will also be keen to hear about any potential impairment charges related to the $12 billion acquisition of TheraGen Biosciences, which could further impact profitability.
Third, attention will pivot to other key pipeline assets. Investors will be watching for readouts from ongoing Phase 3 trials for other high-potential drugs, particularly in oncology and immunology, to offset the del-desiran shortfall. Positive data from these trials could help restore confidence in Novartis's internal R&D capabilities. Key support levels for $NVS shares are seen at $92.50, representing a previous trough from late 2023, with resistance now firmly established at the 200-day moving average of $96.55.
Finally, any strategic moves, such as further portfolio streamlining or bolt-on acquisitions aimed at shoring up the pipeline, will be closely watched. The pressure is on Novartis to demonstrate an alternative growth engine to compensate for the significant blow from del-desiran, especially as the company navigates a competitive pharmaceutical landscape with increasing regulatory scrutiny.
